A novel synthetic receptor-based immunoassay for influenza vaccine quantification
Hashem, A. M.; Gravel, C.; Farnsworth, A.; Zou, W.; Lemieux, M.; Xu, K.; Li, C.; Wang, J.; Goneau, M.-F.; Merziotis, M.; He, R.; Gilbert, M.; Li, X.

This publication could be one of several versions: author’s original, accepted manuscript or the publisher’s version. / La version de cette publication peut être l’une des suivantes : la version prépublication de l’auteur, la version acceptée du manuscrit ou la version de l’éditeur.

For the publisher’s version, please access the DOI link below./ Pour consulter la version de l’éditeur, utilisez le lien DOI ci-dessous.

Publisher’s version / Version de l’éditeur:
https://doi.org/10.1371/journal.pone.0055428
PLoS ONE, 8, 2, 2013-02-12

NRC Publications Record / Notice d’Archives des publications de CNRC:
https://nrc-publications.canada.ca/eng/view/object/?id=d692ba1d-c93b-442a-9928-ad2532609e32
https://publications-cnrc.canada.ca/fra/voir/objet/?id=d692ba1d-c93b-442a-9928-ad2532609e32

Access and use of this website and the material on it are subject to the Terms and Conditions set forth at
https://nrc-publications.canada.ca/eng/copyright
READ THESE TERMS AND CONDITIONS CAREFULLY BEFORE USING THIS WEBSITE.

L’accès à ce site Web et l’utilisation de son contenu sont assujettis aux conditions présentées dans le site
https://publications-cnrc.canada.ca/fra/droits
LISEZ CES CONDITIONS ATTENTIVEMENT AVANT D’UTILISER CE SITE WEB.

Questions? Contact the NRC Publications Archive team at PublicationsArchive-ArchivesPublications@nrc-cnrc.gc.ca. If you wish to email the authors directly, please see the first page of the publication for their contact information.

Vous avez des questions? Nous pouvons vous aider. Pour communiquer directement avec un auteur, consultez la première page de la revue dans laquelle son article a été publié afin de trouver ses coordonnées. Si vous n’arrivez pas à les repérer, communiquez avec nous à PublicationsArchive-ArchivesPublications@nrc-cnrc.gc.ca.
A Novel Synthetic Receptor-Based Immunoassay for Influenza Vaccine Quantification

Anwar M. Hashem1,2,6, Caroline Gravel1, Aaron Farnsworth1, Wei Zou3, Michelle Lemieux1, Kangwei Xu4, Changgui Li4, Junzhi Wang4, Marie-France Goneau3, Maria Merziotis3, Runtao He5, Michel Gilbert3,*, Xuguang Li1,6,*

1 Centre for Vaccine Evaluation, Biologics and Genetic Therapies Directorate, Health Canada, Ottawa, Ontario, Canada, 2 Department of Microbiology, Faculty of Medicine, King Abdulaziz University, Jeddah, Saudi Arabia, 3 National Research Council Canada, Institute for Biological Sciences, Ottawa, Ontario, Canada, 4 National Institutes for Food and Drug Control, Beijing, People’s Republic of China, 5 National Microbiology Laboratory, Public Health Agency of Canada, Winnipeg, Manitoba, Canada, 6 Department of Biochemistry, Microbiology and Immunology, University of Ottawa, Ottawa, Ontario, Canada

Abstract

Vaccination is the most effective prophylactic method for preventing influenza. Quantification of influenza vaccine antigens is critically important before the vaccine is used for human immunization. Currently the vaccine antigen quantification relies on hemagglutinin content quantification, the key antigenic component, by single radial immunodiffusion (SRID) assay. Due to the inherent disadvantages associated with the traditional SRID; i.e. low sensitivity, low throughput and need for annual reagents, several approaches have been proposed and investigated as alternatives. Yet, most alternative methods cannot distinguish native hemagglutinin from denatured form, making them less relevant to antigenic analyses. Here, we developed a quantitative immunoassay based on the sialic acid binding property of influenza vaccine antigens. Specifically, we chemically synthesized human and avian influenza virus receptors analogues, N-acetylneuraminic acid-2,6-lactose and N-acetylneuraminic acid-2,3-lactose derivatives with an azidopropyl aglycon, using α-2,6- and α-2,3-sialyltransferases, respectively. The azido group of the two sialylactose-derivatives was reduced and conjugated to mouse serum albumin through a squarate linkage. We showed that the synthetic α-2,6- and α-2,3-sialyl-receptors selectively bound to human and avian-derived hemagglutinins, respectively, forming the basis of a new, and robust assay for hemagglutinin quantification. Hemagglutinin treated at high temperature or low pH was measured differentially to untreated samples suggesting native conformation is dependent for optimal binding. Importantly, this receptor-based immunoassay showed excellent specificity and reproducibility, high precision, less turnaround time and significantly higher sensitivity and throughput compared with SRID in analyzing multiple influenza vaccines.

Copyright: Hashem AM, Gravel C, Farnsworth A, Zou W, Lemieux M, et al. (2013) A Novel Synthetic Receptor-Based Immunoassay for Influenza Vaccine Quantification. PLoS ONE 8(2): e55428. doi:10.1371/journal.pone.0055428

Editor: Valerie A. Ferro, University of Strathclyde, United Kingdom

Received October 9, 2012; Accepted December 22, 2012; Published February 12, 2013

Funding: AMH is supported by a scholarship from King Abdulaziz University, through the Saudi Arabian Cultural Bureau in Canada. This work was supported by the Canadian Regulatory Strategy for Biotechnology. The funders had no role in study design, data collection and analysis, decision to publish, or preparation of the manuscript.

Competing Interests: The authors have declared that no competing interests exist.

* E-mail: michel.gilbert@nrc-cnrc.gc.ca (MG); sean.li@hc-sc.gc.ca (XL)

Introduction

Influenza virus is a highly contagious respiratory pathogen which causes serious health effects worldwide. The continuous evolution of influenza virus due to the constant immune pressure as well as the occasional reassortment because of the segmented nature of viral genome are responsible for the occurrence of annual epidemics and periodic pandemics, respectively. The detrimental impact of influenza on human health can never be overstated. Indeed, there are up to 5 million cases of illness and up to 500,000 deaths associated with influenza every year [1,2,3].

Among the three known genera of influenza viruses, influenza A and B are mainly associated with human disease [1]. The two membrane-embedded surface glycoproteins, hemagglutinin (HA) and neuraminidase (NA) play crucial roles in the virus life cycle. While HA is involved in virus attachment to host cell surface receptors and subsequent entry into target cells by membrane fusion, NA is required for virus release from infected cells [4]. Although several studies have highlighted the role of NA in protection [5,6,7,8,9,10,11], HA is considered to be the main target for neutralizing antibodies upon natural infection or vaccination. There are at least 16 HA subtypes of influenza A virus that have been identified in aquatic birds [1,12], but only strains from H1, H2 and H3 subtypes have become fully adapted to humans [12]. On the other hand, HA from influenza B viruses is classified into two lineages only, B/Victoria/2/87-like and B/Yamagata/16/88-like viruses, [13]. Influenza HA binds to host receptors, sialic acids (SA), which are linked to galactose. The linkage between the SA and the galactose determines the species preference of each HA. In particular, HA from human adapted viruses binds to SAα2,6-Gal, whereas avian HA preferentially binds to SAα2,3-Gal receptors [14,15].

Typically, seasonal influenza vaccines are trivalent containing two influenza A (H1N1 and H3N2) strains and one influenza B strain [16,17]. They predominantly induce HA strain-specific neutralizing antibodies. As indicated, the antigenic epitopes of the virus constantly evolve, making it necessary to annually update the
virus seed strains and the reagents for vaccine potency assays. For more than 30 years, single radial immunodiffusion (SRID) has been used to standardize influenza vaccine potency and for vaccine lot release by most jurisdictions around the globe [18,19]. SRID is a relatively simple, cheap and reproducible method which quantifies the antigenic HA in vaccine preparations against a homologous HA reference antigen [20,21]. Several clinical trials have shown that SRID data correlate well with seroconversion and vaccine efficacy [22,23,24]. However, there are inherent disadvantages associated with SRID including the need to generate annual reference reagents (homologous antigens and corresponding subtype-specific antisera) by the WHO collaborating centres. This is a complex and time-consuming process representing a regulatory hurdle for timely release of vaccine lots as was witnessed during the H1N1 2009 pandemic [19]. In addition, it is not very sensitive for very low-dose vaccines [17], and it is a low throughput assay [19]. Therefore, the WHO and the European Medicines Agency (EMA) encourage the development of alternative methods for influenza vaccine standardization to complement or replace SRID.

Various research groups have investigated and continue to develop new approaches to address this issue. An early study showed that size exclusion-high performance liquid chromatography (SE-HPLC) is able to isolate the HA1 and HA2 subunits from vaccine preparations containing HA0 and provide a profile of protein components in vaccines according to protein size [25]. Several other groups also reported that reversed-phase HPLC (RP-HPLC) could be used to accurately separate and quantify absolute amounts of HA1 subunits from the three strains contained in trivalent formulations [26,27,28]. Moreover, Kapteyer et al. showed that RP-HPLC can be used with formaldehyde-inactivated egg or cell-derived vaccines, as well as subunit vaccines [29]. Interestingly, combining the two methods SE and RP-HPLC in two-dimensional (2D) HPLC resulted in higher sensitivity and selectivity for HA1 quantification [30]. Tandem mass spectrometry (MS)-based approaches were also investigated for characterization of influenza vaccines [31,32,33,34]. Although these techniques have several advantages, especially in selectivity and sensitivity, they require expensive equipment and highly trained technical staff. During the 2009 pandemic, a few initiatives were undertaken to quantify HA content using some of these alternative methods for rapid release of vaccine lots. For example, the Chinese State Food and Drug Administration (SFDA) approved the use of SDS-PAGE and total protein measurement for HA content determination [35]. Moreover, a few clinical trials were based on potency values obtained by different manufacturers using HPLC as an alternative method in the US and Europe [19,36]. While SDS-PAGE showed 88–120% consistency with SRID data [35], HPLC showed an underestimation of HA content in tested vaccines when they were re-evaluated using SRID [19,36].

In addition to the reported physiochemical methods, alternative immunoassays for potency determination of influenza vaccine were also investigated. We previously generated universal anti-HA antibodies (Uni-1 Abs) targeting the highly conserved fusion peptide which bound to virtually all subtypes of HA [37,38,39]. Accordingly, they were used in multiple assay formats such as competitive ELISA (cELISA), slot blot and Western blot [40,41] to analyze HA content in vaccines. More recently, Legastelois et al. reported two broadly reactive avian-glycan IgM mAbs [42] which were used in sandwich ELISA assays for HA quantification. These universal antibodies-based assays are very useful in quality control, especially for monoclonal bulks and in-process manufacturing. However, they cannot be used with trivalent vaccines because they do not distinguish between the different HA subtypes. Although, an ELISA binding assay was previously developed based on binding of soluble horseradish peroxidase-labelled sialylglycoproteins to influenza viruses adsorbed to lectin in microplates, this assay was mainly tested for receptor-binding properties and not evaluated for vaccine quantification [43].

Table 1. Vaccines, recombinant HA proteins and antibodies used in this study.

| Human Vaccine (subtype) | Donor strains |
|-------------------------|---------------|
| Influenza A (H1N1)      | Influenza A/California/7/2009 |
| Influenza A (H3N2)      | Influenza A/Perth/16/2009(H3N2)-like* |
| Influenza B             | Influenza B/Brisbane/60/2008 |

| Recombinant HA          | Donor strains |
|-------------------------|---------------|
| A/H1                    | Influenza A/New Caledonia/20/1999 |
| A/H5                    | Influenza A/Vietnam/1203/2004 |
| A/H7                    | Influenza A/Netherlands/219/03 |
| B                      | Influenza B/Malaysia/2506/2004 |

| Antibodies              | Immunogen     |
|-------------------------|---------------|
| Sheep anti-H1 A/California/7/2009(H1N1) | Influenza A/California/7/2009 |
| Sheep anti-H3 A/Perth/16/2009(H3N2)-like | Influenza A/Wisconsin/15/2009 |
| Sheep anti-HB B/Brisbane/60/2008 | Influenza B/Brisbane/60/2008 |
| Sheep anti-H1 A/New Caledonia/20/1999 (H1N1) | Influenza A/New Caledonia/20/1999 |
| Sheep anti-H5 A/Vietnam/1203/2004 (H5N1) | Influenza A/Vietnam/1203/2004 |
| Rabbit Uni-1 Abs (universal anti-HA antibody) | Influenza HA fusion peptide [37,38,39] |
| Rabbit anti-H1 A/California/7/2009(H1N1) | Influenza A/California/7/2009 |
| Rabbit anti-H3 A/Victoria/210/2009(H3N2) | Influenza A/Victoria/210/2009 |
| Rabbit anti-HB B/Brisbane/60/2008 | Influenza B/Brisbane/60/2008 |

*Monovalent vaccine strain was A/Victoria/210/2009 (H3N2) and trivalent vaccine strain was A/Wisconsin/15/2009 (H3N2). doi:10.1371/journal.pone.0055428.t001
SRID remains the most effective assay to quantify trivalent vaccines despite the development of several alternative assays, since it can presumably measure the native trimeric form of HA protein [44], which is known to be correlated with vaccine stability and immunogenicity [45,46,47,48]. In addition, SRID is simple and does not require significant technological skill, making international comparisons or standardization relatively straightforward. On the other hand, most of the recently reported physiochemical and immunological methods do not differentiate between denatured and native protein structures, thus limiting their use in terms of vaccine lot release [19]. Clearly, there is still a need for additional approaches which would facilitate better vaccine quality control. Here, we report the development of an enzyme-linked immunosorbent assay (ELISA) based on the binding of HA to synthetic SA receptors. We present the detailed chemical synthesis process of the receptors and determined that they could distinguish the two types of HA (human vs. avian). When compared with SRID, the receptor-based ELISA (R-ELISA) was found to have higher sensitivity, higher throughput, less turnaround time and, most importantly, it is a stability-indicating assay.

**Materials and Methods**

**Vaccines, Recombinant Proteins and Antibodies**

Table 1 lists the vaccine strains, recombinant HA proteins and antibodies used in this study. The annual influenza reference antigens (H1N1, H3N2 and B) as well as the reference sheep antibodies were kindly provided by the National Institute for Biological Standards and Control (NIBSC), Potters Bar, U.K. The strain specific rabbit antibodies were purchased from Sino Biological Inc. (Beijing, P.R. China). The recombinant HAs were purchased from Proteins Sciences Corporation (Meriden, CT).

| Table 2. Characterization of conjugates by MALDI-MS. |
|-----------------------------------------------|
| **Conjugate** | **MW of receptor** | **MW of MSA** | **Average MW of conjugate** | **Receptor/MSA** |
|----------------|---------------------|---------------|-----------------------------|-----------------|
| A (avian receptor) α-2,3-sialyllactoside-MSA | 770 | 65,859 | 79,646 | 18 |
| B (human receptor) α-2,6-sialyllactoside-MSA | 770 | 65,859 | 77,332 | 15 |

The ratio of receptors to MSA was estimated by mass spectrometry analysis. MSA has a molecular weight of 65,859 Dalton by MALDI-MS, whereas the molecular weights of the α-2,3- and α-2,6-sialyllactoside conjugates are averaged around 79,646 Da and 77,332 Da, respectively, indicating 18 molecules of α-2,3-sialyllactoside are attached to MSA, and 15 of α-2,6-sialyllactoside to MSA.

doi:10.1371/journal.pone.0055428.t002

![Figure 1. Synthesis of the avian and human influenza receptors and conjugation to mouse serum albumin (MSA).](https://example.com/figure1.png)

Schematic representation of steps involved in the synthesis and conjugation of the avian and human receptors. A is the avian receptor (α2,3-sialyllactoside-MSA) and B is the human receptor (α2,6-sialyllactoside-MSA). For the ratio of receptors to MSA as estimated by mass spectrometry analysis (MALDI-MS) see Table 2.

doi:10.1371/journal.pone.0055428.g001
Synthesis of the Avian and Human Influenza Receptors

Sialyltransferases. The avian receptor was synthesized using the Campylobacter jejuni Cst-I α-2,3-sialyltransferase (construct CST-06) which was expressed and purified as described before [49]. The human receptor was synthesized using the α-2,6-sialyltransferase from Photobacterium sp. JT-ISH-224 which was previously characterized [50,51,52]. A synthetic gene containing amino acids 110 to 514 of the α-2,6-sialyltransferase from Photobacterium sp. JT-ISH-224 (GenBank accession number BAF92026) was obtained from GenScript (Piscataway, NJ). The gene encoding the truncated α-2,6-sialyltransferase was transferred to plasmid pCWori+ to be expressed as a fusion protein containing the Escherichia coli maltose-binding protein (without the leader peptide) at the N-terminus (construct PDS-06). The fusion protein was expressed in E. coli AD202 (CGSC 7297) and purified on amylose resin according to the manufacturer’s instructions (New England Biolabs, Beverly, MA).

Synthesis of N-acetylneuraminic acid (NeuAc)-α-2,3-Galβ-1,4-Glcβ-O-propylazide (avian receptor). The α-2,3-sialyllactoside was synthesized as described previously [53] using the α-2,3-sialyltransferase CST-06 and azidopropyl lactoside [54].

Synthesis of N-acetylneuraminic acid (NeuAc)-α-2,6-Galβ-1,4-Glcβ-O-propylazide (human receptor). The reaction mixture included 107 mg of azidopropyl lactoside (10 mM final concentration), 14 mM CMP-NeuAc, 50 mM Mes pH 6 and 5 units of the α-2,6-sialyltransferase PDS-06. The reaction was incubated for 70 minutes at 37°C to ensure the completion of the reaction as revealed by thin layer chromatography (TLC) and detection by charring in 5% (v/v) H2SO4-RhOH. Purification was conducted on a Bio-Gel P-2 column using water as eluent, yielding 70 mg of α-2,6-sialyllactoside in lyophilized form.

Reduction of azide. To a solution of azidopropyl sialyllactoside (30 mg) in methanol (5 mL) was added 10% Pd-C (50% water, 10 mg). The mixture was stirred under hydrogen at balloon pressure for 20 minutes until the reaction was complete. The filtrate was concentrated to generate aminopropyl sialyllactoside (20 mg).

Figure 2. Binding specificity of human and avian synthetic receptors. ELISA plates were coated with either (A) the human α-2,6-sialyllactoside-MSA receptor or (B) the avian α-2,3-sialyllactoside-MSA receptor. Various types of recombinant HA proteins were tested. The binding of each recombinant HA to either receptor was detected with strain-specific antibodies and Uni-1 Abs which are universal antibodies against all HA proteins. Binding is shown as mean of absorbance from three experiments with error bars indicating the standard deviation. doi:10.1371/journal.pone.0055428.g002

Figure 3. Effect of heat treatment on vaccine binding to the synthetic receptor. Influenza strains included in 2010–2011 vaccine (A) A/California/7/2009(H1N1), (B) A/Victoria/210/2009(H3N2) and (C) B/Brisbane/60/2008(Victoria-like) were incubated at 4°C, 50°C or 100°C for 1 hour, followed by measurements with both SRID and R-ELISA using the corresponding rabbit strain-specific antibodies. Each treatment was tested in triplicate/experiment and the experiment was repeated twice. Results are shown as mean of absorbance from two experiments with error bars indicating the standard deviation. (See also Figure S1). doi:10.1371/journal.pone.0055428.g003
Activation of receptors. 10 mg of 10% (w/w) Pd-C (as a powder containing 50% water) was added to a solution of 30 mg azidopropyl sialyllactoside in 5 mL of methanol. To a solution of aminopropyl sialyllactoside (20 mg) in phosphate buffered saline (0.8 g NaCl, 0.2 g KCl, 1.44 g Na$_2$HPO$_4$ and 0.24 g KH$_2$PO$_4$, pH 7.2) PBS-MeOH (1.6 mL, 5:3) was added diethyl squarate (40 µL) at pH 7 adjusted using sat. NaHCO$_3$. The reaction was monitored by TLC analysis. After completion of the reaction the mixture was loaded onto a Biogel P-2 column and monoethyl squarate derivatives were obtained (15 mg). Both monoethyl squarate intermediates gave similar characteristic proton spectra. $^1$H NMR (400 MHz, D$_2$O) $d$ 1.26–1.32 (m, 3H, C$_5$H$_3$CH$_2$O), 1.59 (dd, 1H, H3a, J = 12.4, 12.4 Hz), 1.88 (s, 3H, NAc), 2.56 (dd, 1H, H3e, J = 12.4, 4.4 Hz), 4.27 (d, 1H, H1, Gal, J = 8.0 Hz), 4.33 (d, 1H, H1, Glc, J = 8.0 Hz), 4.48 (q, 2H, CH$_3$C$_{2}$H$_2$O, J = 6.8 Hz).

Conjugation. Monoethylsquarate derivative (15 mg) and 30 mg murine serum albumin (Sigma-Aldrich Canada Ltd., Oakville, ON) was dissolved in 0.1 M Na$_2$HPO$_4$ (4 mL) at pH 9 adjusted using 0.1 M NaOH. The mixture was kept at room temperature for 30 hours. The conjugation was confirmed by HPLC analysis and the conjugates were purified on a Biogel A 0.5 column using PBS as eluent. The fractions were collected, dialyzed and lyophilized to generate the final conjugates (24 mg). The ratio of receptors to MSA was estimated by matrix-assisted laser desorption/ionization mass spectrometry (MALDI-MS) (see Table 2).

Enzyme-linked Immunosorbent Assay (ELISA)

Indirect ELISA was performed as described previously with minor modifications [55]. Briefly, 96-well plates (Nunc, Mississauga, ON) were coated overnight at 4°C with 100 µL of 4 µg/mL of human ($\omega$-2,6-sialyllactoside-MSA) or avian ($\omega$-2,3-sialyllactoside-MSA) receptors in 0.05 M carbonate buffer (pH 9.6) per well. The plates were then washed 3 times with PBS containing 0.05% (v/v) Tween-20 (PBS-T), followed by blocking with 5% (w/v) skim milk in PBS-T for 1 hour. After 3 additional washes with PBS-T buffer, 100 µL of vaccines were added in a half-log serial dilution starting from 10 µg/mL in PBS-T. The plates were then incubated at 37°C for 1 hour. After 6 washes with PBS-T buffer, reference sheep antibodies (1:2000 dilution), strain-specific rabbit antibodies (1 µg/mL) or Uni-1 Abs (1:2000 dilution) were added in PBS-T with 5% (w/v) skim milk and the results are shown as mean of absorbance with error bars indicating the standard deviation.

Figure 4. Effect of low pH treatment on vaccine captured by the synthetic receptor. Influenza strains included in 2010–2011 vaccine (A) A/California/7/2009(H1N1), (B) A/Victoria/210/2009(H3N2) and (C) B/Brisbane/60/2008(Victoria-like) were incubated at the indicated pH for 1 hour and then neutralized to pH 7.2 prior to measurement by both SRID and R-ELISA using the corresponding rabbit strain-specific antibodies. Each treatment was tested in triplicate/experiment and the experiment was repeated at least thrice. Results are shown as mean with error bars indicating the standard deviation.
doi:10.1371/journal.pone.0055428.g004

Figure 5. Specificity of synthetic receptor based ELISA. Influenza strains included in 2010–2011 vaccine (A/California/7/2009(H1N1), A/Victoria/210/2009(H3N2) and B/Brisbane/60/2008(Victoria-like)) (10 µg/ml) or a trivalent sample (containing 10 µg/ml from each strain) were measured by R-ELISA using (A) Rabbit anti-HA from Influenza A/California/7/2009(H1N1), (B) Rabbit anti-HA from Influenza A/Perth/16/2009 Like(H3N2) or (C) Rabbit anti-HA from Influenza B/Brisbane/60/2008. Each treatment was tested in triplicate/experiment and the experiment was repeated thrice. Results are shown as mean of absorbance with error bars indicating the standard deviation.
doi:10.1371/journal.pone.0055428.g005
plates were incubated at 37°C for 1 hour. After extensive washing, peroxidase-conjugated donkey anti-sheep IgG (Sigma-Aldrich Canada Ltd., Oakville, ON) or goat anti-rabbit IgG (GE Healthcare, Baie d’Urfe, QC) was added at 1:2000 dilution as recommended by the supplier and plates were incubated for 1 hour at 37°C. After 6 washes with PBS-T, tetramethylbenzidine (TMB) substrate (Cell Signaling Technology, Inc. Danvers, MA) was added and incubated for 30 minutes for colorimetric development. The reaction was stopped with 0.16 M sulfuric acid and the absorbance was read spectrophotometrically at 450 nm to quantify the HA antigens bound to the receptors at each dilution. A reference homologous antigen was included on each ELISA plate. Vaccine concentrations were determined using parallel line analysis to compare absorbance from each vaccine to that of the reference standard in 4-parameter regression model using Combistats 4.0 software.

Single-radial-immunodiffusion Assay (SRID)

HA content in the different monovalent hemagglutinin preparations or trivalent vaccines was determined using SRID assay as previously described [56]. Briefly, 1% (w/v) agarose gels were cast with the appropriate HA antiserum (NIBSC) and wells were punched into the solidified gels. Vaccine and control samples were treated for 20 minutes at room temperature with Zwittergent 3–14 (Calbiochem-Behring Corp., La Jolla, CA) at a final concentration of 1% (w/v). The samples were then diluted with 1% (w/v) Zwittergent 3–14, loaded into the wells and incubated for 24 hours at room temperature. Following incubation, the gels were washed, mounted onto Gelbond film (Lonza, Rockland, ME, USA), dried and stained with Coomassie Brilliant Blue. The dried gels were scanned and potency estimates were determined through either the comparison of ring diameters or the number of pixels contained in the surface area of each ring compared to the corresponding reference antigen. Each sample was tested at least three times at four dilutions.

Figure 6. Precision of synthetic receptor based ELISA. Three expected ratios (80%, 100% and 120%) of the HA from each influenza reference strain in the 2010–2011 vaccine (A) A/California/7/2009(H1N1), (B) A/Victoria/210/2009(H3N2) and (C) B/Brisbane/60/2008(Victoria-like). Vaccine samples with known amounts of HA (pre-determined by SRID) were employed in spiking and recovery assays using strain-specific rabbit antibodies. Each sample was tested in triplicate. Data are shown as mean ± SD from two experiments (see also Figure S3). For HA concentrations obtained from each strain at each ratio see Table 3.

doi:10.1371/journal.pone.0055428.g006

| Observed Concentration (μg/ml) | Expected Concentration (μg/ml) | Recovery (%) |
|-------------------------------|-------------------------------|--------------|
| **Influenza A/California/7/2009(H1N1) Vaccine** |                               |              |
| 10.5±1.1                      | 10                            | 105.3±10.8   |
| 12.9±1.6                      | 12                            | 107.6±13.2   |
| 8.0±0.5                       | 8                             | 100.3±5.9    |
| **Influenza A/Perth/16/2009(H3N2)-like** |                               |              |
| 9.1±0.6                       | 10                            | 90.7±6.5     |
| 11.4±1.1                      | 12                            | 95.2±9.1     |
| 7.9±0.4                       | 8                             | 98.5±5.0     |
| **Influenza B/Brisbane/60/2008 Vaccine** |                               |              |
| 9.7±1.4                       | 10                            | 97.2±13.6    |
| 11.8±1.8                      | 12                            | 98.3±14.8    |
| 8.0±1.5                       | 8                             | 99.5±18.4    |

Each sample was tested in triplicate. Data are shown as mean ± SD from two experiments. HA concentrations were obtained using strain-specific rabbit antibodies.

doi:10.1371/journal.pone.0055428.t003
Thermal Treatment

Monovalent vaccines were incubated at 4°C, 50°C or 100°C for one hour. Then, HA content in the treated vaccines was measured by SRID and R-ELISA using the corresponding sheep or rabbit strain-specific antibodies.

Low pH Treatment

The pH treatment was described previously [46]. Briefly, the pH of vaccine samples in PBS was altered by adding an appropriate volume of 0.1 M acetate buffer to reach the desired pH. After 1 hour at 37°C the reaction mixtures were re-neutralized to pH 7.2 with 0.1 M NaOH. HA content in the treated vaccines was measured by SRID and R-ELISA using the corresponding sheep or rabbit strain-specific antibodies.

Results

Enzymatic Sialylation of Azidopropyl Lactoside

Selectively Produced α-2,3-sialyllactoside (Avian Receptor) and α-2,6-sialyllactoside (Human Receptor)

Azidopropyl lactoside (Gal-β-1,4-Glc-β-O-(CH₂)₃-N₃) was used as the precursor for the synthesis of the HA receptors (Figure 1). Recombinant bacterial sialyltransferases were used to add the terminal sialic acid residues with the appropriate linkage specificity for each receptor. An α-2,3-sialyltransferase from Campylobacter jejuni [49] was used to synthesize the avian receptor and an α-2,6-sialyltransferase from Photobacterium sp. JT-ISH-224 [50] for the human receptor. The azido group of the aglycon of each synthetic receptor was reduced to an amine by catalytic hydrogenation (H₂/Pd-C). In order to conjugate the sialyllactoside receptors to a protein carrier, e.g. mouse serum albumin (MSA), we employed

Table 4. Intra-assay variation.

| Monovalent Vaccine | Expected Concentration (µg/ml) | Observed Concentration (µg/ml) | Coefficient of Variation (CV) |
|--------------------|-------------------------------|--------------------------------|-------------------------------|
|                    | SRID R-ELISA                  | SRID R-ELISA                  |                               |
| A/California/7/2009(H1N1) | 37.0 33.07±1.78 33.69±2.34 | 11.42% 6.96%                    |                               |
| A/Victoria/210/2009(H3N2) | 26.0 21.69±1.27 25.03±1.53 | 5.9% 6.1%                        |                               |
| B/Brisbane/60/2008 | 27.0 24.47±1.76 25.62±1.73 | 7.2% 6.76%                        |                               |

Each sample was tested in triplicate. Data are shown as mean ± SD from five experiments.

doi:10.1371/journal.pone.0055428.t004

Table 5. Quantification of HA in vaccines.

| Influenza Strain | Vaccine Type | Expected Concentration (µg/ml)* | Observed Concentration (µg/ml) |
|------------------|--------------|---------------------------------|-------------------------------|
|                  |              | SRID R-ELISA                    | SRID R-ELISA                  |
| A/California/7/2009(H1N1) | Monovalent 1 37.0 33.3 (29.3–37.4) 33.7 (28.7–39.6) |                               |
|                   | Monovalent 2 33.4 (29.2–37.8) 34.6 (29.4–40.6) |                               |
|                   | Monovalent 3 37.4 (33.2–42) 35.2 (30–41) |                               |
|                   | Trivalent 1 30.0 41.7 (37.6–47.2) 40.5 (39–42) |                               |
|                   | Trivalent 2 35.5 (31.4–41.1) 43.4 (41.7–45.1) |                               |
|                   | Trivalent 3 39.7 (37.7–41.9) 25.5 (24.2–26.9) |                               |
|                   | Monovalent 1 26.0 22.1 (18.8–25.5) 24.1 (22.6–25.6) |                               |
|                   | Monovalent 2 21.8 (18.7–24.8) 26.8 (25.1–28.6) |                               |
|                   | Monovalent 3 19.9 (16.6–23.2) 25.4 (21.8–27) |                               |
|                   | Trivalent 1 30.0 46.2 (43.6–49.3) 33.4 (32.5–34.4) |                               |
|                   | Trivalent 2 43.6 (39.2–49.7) 35.6 (34.6–36.6) |                               |
|                   | Trivalent 3 41.8 (38.1–46.9) 34.4 (33.2–35.7) |                               |
| A/Perth/16/2009(H3N2)-like* | Monovalent 1 27.0 26.1 (24.8–27.4) 28.9 (27.1–30.7) |                               |
|                   | Monovalent 2 23.2 (21.9–24.4) 24.8 (23.4–26.3) |                               |
|                   | Monovalent 3 25.9 (24.6–27.2) 26.6 (25.1–28.2) |                               |
|                   | Trivalent 1 30.0 32.8 (30.5–35.5) 28.4 (27.2–29.6) |                               |
|                   | Trivalent 2 36.3 (33.6–39.6) 27.4 (26.8–27.9) |                               |
|                   | Trivalent 3 36.0 (34.4–37.9) 31.7 (30.8–32.7) |                               |

Each sample was tested in triplicate.

Data are shown as mean (95% Confidence interval).

*Monovalent vaccine strain was A/Victoria/210/2009(H3N2) and trivalent vaccine strain was A/Wisconsin/15/2009 (H3N2).

*Expected concentration is labeled values initially determined by SRID.

doi:10.1371/journal.pone.0055428.t005

*Intra-assay variation.

*Expected concentration is labeled values initially determined by SRID.

**Influenza Strain Vaccine Type Expected Concentration (µg/ml) Observed Concentration (µg/ml) Coefficient of Variation (CV) SRID R-ELISA SRID R-ELISA...
by mass spectrometry analysis. MSA has a molecular weight of 65,939 Da by MALDI-MS, whereas the molecular weights of the \( \alpha \)-2,3- and \( \alpha \)-2,6-sialyllactoside conjugates are on average around 79,646 Da and 77,332 Da, respectively, indicating 18 molecules of \( \alpha \)-2,3-sialyllactoside are attached to MSA, and 15 of \( \alpha \)-2,6-sialyllactoside to MSA (Table 2).

### Synthetic Receptors Differentiate between Avian and Human HA

To investigate the binding specificity of the synthetic receptors, we tested the binding of different recombinant HA proteins to either human or avian receptors in ELISA. As shown in Figure 2, human H1 (influenza A/New Caledonia/20/1999) protein showed classic human receptor preference compared to avian H5 (Influenza A/Vietnam/1203/2004) and H7 (Influenza A/Netherlands/219/03) proteins, which preferentially bound to the \( \alpha \)-2,3-sialyllactoside-MSA receptors only. In contrast, HA from influenza B/Malaysia/2506/2004 virus bound to both receptors. This is consistent with earlier demonstrations that influenza B viruses belonging to the Victoria-like lineage have binding specificities to both human and avian receptors [58]. These results confirm that the receptors are functional and show specificity in binding.

### R-ELISA Detects Native HA Trimer Rather than Denatured Forms

Measurement of antigenic HA trimer rather than denatured HA in vaccines is a critical requirement in any alternative vaccine potency assay [19]. To investigate whether the R-ELISA could serve as a stability-indicating assay, we tested the effect of temperature on HA of the influenza strains included in 2010–2011 vaccine (A/California/7/2009(H1N1), A/Victoria/210/2009(H3N2) and B/Brisbane/60/2008(Victoria-like)). As shown in Figure 3, heat-treatment of HA in these vaccines clearly reduced the binding between HA and the synthetic receptor as detected by both SRID and R-ELISA, with the latter being more sensitive in detecting temperature-induced structural changes. Similar results were also obtained when a different source of antibodies was used in R-ELISA (sheep anti-H1, H3 or type B HA) (Figure S1, supplementary materials).

Acidic conditions also result in irreversible conformational change of HA [59,60]. Therefore we also evaluated the effect of low pH treatment on HA binding to the receptor. As shown in Figure 4, all HA samples tested (H1, H3 and type B) had substantially reduced binding to the synthetic receptors after exposure to low pH conditions; similar to SRID. Collectively, these results indicate that R-ELISA is capable of detecting trimeric HA protein in its native conformation.

### Antigen Specificity and Interference in the R-ELISA

Because the seasonal vaccines are trivalent (H1N1, H3N2 and influenza B), we next investigated whether the R-ELISA is suitable for measurement of different HA antigens in the current trivalent vaccines. As shown in Figure 5, the strain-specific antibodies used to detect each specific virus showed no detectable cross-reactivity. More importantly, binding curves obtained from each antigen in monovalent vaccine were very similar to those in the trivalent preparations, suggesting that this assay can accurately quantify specific HA strains in either monovalent or trivalent formulations. Furthermore, we tested the effect of egg or mammalian cell adaptation on binding of vaccines to the human receptors. This experiment showed that both sources can be used in our R-ELISA (Figure S2, supplementary materials).

### Precision and Curve Fitting of R-ELISA

Known amounts of HA (pre-determined by SRID) were employed in spiking and recovery assays to determine the precision of the R-ELISA. For each strain, three expected ratios of the reference concentration were employed (80%, 100% and 120%). As shown in Figure 6 and Figure S3 (supplementary materials), the dose response curves for the three ratios satisfy the 4-PL model assumptions (i.e., regression, linearity and parallelism). Most importantly, the HA concentrations obtained from each strain were very close to the expected ratios (Table 3). Furthermore, these data clearly show the high sensitivity of the R-ELISA for very low vaccine concentrations with detection range of 0.1–10 μg/mL.

### Quantification of HA Protein Content in Influenza Vaccine Using R-ELISA and SRID

We first conducted experiments to compare inter-assay variability between R-ELISA and SRID. In these experiments, samples were tested in triplicates at each dilution and each experiment was repeated 5 times. We found that in terms of variability, as suggested by CV, R-ELISA is performing at least as well as SRID. Interestingly, in the case of A/Victoria/210/2009 (H3N2) the HA amounts obtained by R-ELISA were much closer to predicted HA concentration (Table 4). We next used the R-ELISA to quantify HA in both multiple monovalent and trivalent samples in parallel with SRID against the same international reference antigens. As shown in Table 5, in comparison to the values determined by SRID, values obtained by R-ELISA were again very close to expected values, confirming that R-ELISA can be a viable alternative assay for HA quantifications.

### Discussion

A variety of alternative assays have been developed for the potency determination of influenza vaccines since SRID is a tedious procedure and needs annually updated strain-specific antigens and antibodies as reference reagents. However, SRID remains useful primarily because it is sensitive to conformational change in the HA protein trimer and can therefore be used for stability analyses. Most of the reported alternative assays, particularly physiochemical assays, cannot determine the stability of the vaccines due to the use of denaturing conditions for protein separation or trypsin-cleavage of the proteins. Therefore, an alternative assay for potency determination of influenza vaccine would preferably be quantitative in a high throughput fashion and capable of analyzing trivalent vaccines and determining vaccine stability.

The R-ELISA reported here employs synthetic receptors to specifically capture correctly folded HA proteins followed by detection using strain-specific antibodies. The NA activity in the vaccine products does not appear to significantly affect the binding between HA and the synthetic receptor as the data from R-ELISA are comparable to that obtained from SRID. Our comparative studies revealed that R-ELISA performs at least as well as SRID in precision and reproducibility. Moreover, the use of 96-well ELISA plates facilitates high-throughput handling of samples and automation. It is of note that, in addition to its suitability for determining each viral HA component in trivalent vaccines, R-
ELISA is more sensitive than SRID in detecting HA conformation changes induced by heating and at least as good as SRID in low pH conditions, an observation which needs to be better understood. However, the decreased signal in R-ELISA following lower pH treatment of the vaccine (Fig. 4) is mostly due to that the acidic pH-treated HA had lost its binding to the receptor not due to a weakened detection by the anti-HA polyclonal antibodies (Figure S4, supplementary materials). The R-ELISA may be more sensitive to changes in the native structure of HA because it is based on binding between the receptor and HA in the absence of a detergent (Zwittergent), whereas SRID is based on antigen-antibody precipitation in the presence of high concentration of detergent (usually 1% zwittergent). It needs to be mentioned that the use of 1% of Zwittergent is necessary in SRID to disperse samples, thereby allowing antigen diffusion in agarose. Yet, there is no such treatment of samples in R-ELISA, which might more accurately reflect the native conformation of the HA protein. Furthermore, the decreased absorbance reading following heat treatment in R-ELISA is suggestive of a loss in HA binding to the receptor. While the difference in HA contents between SRID and R-ELISA following heat treatment, particularly at 50°C, needs to be further investigated (Fig. 3), the purpose of this experiment is to examine whether heating can affect the HA binding to receptors. Moreover, it should be noted that future animal studies could be considered to verify the significance of HA contents obtained from R-ELISA following heat treatment of samples.

While the synthetic receptors with α-2,6- and α-2,3-linked sialic acids demonstrated excellent selectivity by binding to human and avian-derived HAs, respectively, this study is focused on characterization of the α-2,6 receptor-based R-ELISA for the analysis of human vaccines. We did not conduct full characterization of the α-2,3 receptor since sufficient avian vaccine samples were not available for assay validation beyond the specificity determination of binding using recombinant human and avian HA (Figure 2). Nevertheless, the selective binding of α-2,3 receptors to recombinant avian HA (H5 and H7) indicates the potential utility of this type of assay for stability tests of avian influenza vaccines, which are being developed or considered by numerous vaccine developers as a strategy to confront future pandemics through stockpiling candidate vaccines derived from avian viruses.

The R-ELISA reported here depends on the availability of the synthetic (N-acetylneuraminic acid-2,6-lactose) receptors which represents a technical challenge. However they can be readily synthesized as required using the protocol described here. Moreover, it would be interesting to investigate the potential lactoseamine derivatives in this R-ELISA platform as they might show better binding to influenza viruses [61]. Like any new assay, the R-ELISA still requires vigorous international validation for its suitability as a routine influenza vaccine quality control method. Yet, this assay differs from other previously reported alternative assays for influenza potency in that it is a stability-indicating immunoassay, which is an important requirement for assaying vaccine potency.

Conclusions

Recently, several approaches have been proposed and investigated as alternatives to replace the traditional SRID method for HA quantification in vaccines. However, despite all of the inherent disadvantages (i.e. low sensitivity, low throughput, need for annual reagents), SRID remains the method of choice for vaccine potency determination since the majority of the previously reported assays cannot distinguish the native or antigenic HA from the denatured form of this protein. The influenza synthetic receptor-based ELISA (R-ELISA) developed here not only selectively quantify native HA trimers but also distinguishes itself from the traditional SRID assay in terms of higher throughput, greater sensitivity and shorter turnaround time.

Supporting Information

Figure S1 Effect of heat treatment on vaccine binding to the synthetic receptor. Influenza strains included in 2010–2011 vaccine (A) A/California/7/2009(H1N1), (B) A/Victoria/210/2009(H3N2), and (C) B/Brisbane/60/2008/Victoria-like were incubated at 4°C, 50°C or 100°C for 1 hour then measured by both SRID and R-ELISA using the corresponding sheep strain-specific antibodies. Each treatment was tested in triplicates and experiment was repeated twice. Results are shown as mean of absorbance and error bars indicate the standard deviation. (TIF)

Figure S2 Binding of egg and cell-derived vaccines. Binding of egg or cell-derived influenza A/California/7/2009(H1N1) strain starting at 10 μg/ml was tested by the R-ELISA using the strain-specific (A) Sheep anti-HA or (B) Rabbit anti-HA Abs. Each treatment was tested in triplicates and experiment was repeated twice. Results are shown as mean of absorbance and error bars indicate the standard deviation. (TIF)

Figure S3 Precision of synthetic receptor based ELISA. Three expected ratios (80%, 100% and 120%) of the HA from each influenza reference strain in the 2010–2011 vaccine (A) A/California/7/2009(H1N1), (B) A/Perth/16/2009(H3N2)-like and (C) B/Brisbane/60/2008/Victoria-like as determined by the SRID were employed in spiking and recovery assay using NIBSC sheep antisera. Each sample was tested in triplicates. Data are shown as mean +/- SD from two experiments. (TIF)

Figure S4 pH 6.0 treatment of vaccine does not result in a loss of binding between the vaccine and the polyclonal antibodies. Vaccine sample (H1N1) were treated with lower pH (6.0) and then neutralized to pH 7.2. The samples were then coated to ELISA plates, followed by detection with the same polyclonal Ab used in R-ELISA. The results show that pH 6.0 did not cause a loss of HA binding to the polyclonal Ab. N.B.: when the universal antibody Uni-1 was used, the binding is generally weak in this direct ELISA although pH6.0 does result in a slightly better binding. In contrast, binding between receptor to HA resulted in a better exposure of the fusion peptide epitope which can be detected by Uni-1 as demonstrated by high OD values in Fig. 1. Collectively, these data (Fig. 4 & Figure S4) suggest that following pH 6.0 treatment of vaccine, the significantly decreased signal (Fig. 4A) is due to treatment of HA resulted in a conformational change, causing a substantially weakened capture by the receptor. (TIF)

Acknowledgments

We thank Marsha Russell and Monika Tocchi for technical assistance. We also appreciate editorial editing by Monika Tocchi. Dr. Michael Rosumney and Dr. Daryl Smith (Health Canada) are acknowledged for their critical review of the manuscript.

Author Contributions

Conceived and designed the experiments: AH CG AF WZ CL JW RH MG XL. Performed the experiments: AH CG AF WZ ML CL MFG MM MG XL KX. Analyzed the data: AH CG AF WZ ML CL JW MFG MM
References

1. Zambon MC (1999) Epidemiology and pathogenesis of influenza. J Antimicrob Chemother 44: 5–9.
2. Poland GA, Rottinghaus ST, Jacobson RM (2001) Influenza vaccines: a review and rationale for use in developed and underdeveloped countries. Vaccine 19(17–19): 2216–2220 doi:10.1016/S0264-410X(00)00448-5.
3. Smith NM, Berse JS, Shuy DK, Uyeki TM, Cox NJ, et al. (2006) Prevention and Control of Influenza: recommendations of the Advisory Committee on Immunization Practices (ACIP). MMWR Recomm Rep 55: 1–42.
4. Du L, Zhou Y, Jiang S (2010) Research and development of universal influenza vaccines. Microbes Infect 12(4): 208–209 doi:10.1016/j.micinf.2010.01.001.
5. Schramm JL, Khakpour M, Kilbourne ED (1986) Protective effects of specific immunity to viral neuraminidase on influenza virus infection of mice. J Virol 28(2): 776–786.
6. Rott R, Bchl H, Orlich M (1974) The significance of influenza virus neuraminidase in the pathogenesis of influenza. J Gen Virol 21(3): 35–41.
7. Johansson BE, Grajower B, Kilbourne ED (1993) Infection-permissive neuraminidase activity of influenza virus vaccine and in children in the absence of exogenous humans. PLoS Med 4(2): e139 doi:10.1371/journal.pmed.0040029.
8. Bucher DJ, Li SSL, Kehoe JM, Kilbourne ED (1976) Chromatographic isolation of the hemagglutinin polypeptides from influenza virus vaccine and determination of their amino-terminal sequences. Proc Nat Acad Sci U S A 73(1): 4426.
9. Cate TR, Couch RB, Parker D, Baxter B (1983) Reactogenicity, immunogenicity and rationale for use in developed and underdeveloped countries. Vaccine 19(17–19): 2216–2220 doi:10.1016/S0264-410X(00)00448-5.
10. Rott R, Becht H, Orlich M (1974) The significance of influenza virus neuraminidase in the pathogenesis of influenza. J Virol 28(2): 776–786.
11. Johansson BE, Grajower B, Kilbourne ED (1993) Infection-permissive neuraminidase activity of influenza virus vaccine and in children in the absence of exogenous humans. PLoS Med 4(2): e139 doi:10.1371/journal.pmed.0040029.
12. Stevens J, Blixt O, Tumpey TM, Taubenberger JK, Paulson JC, et al. (2006) Comparative analysis of evolutionary mechanisms of the hemagglutinin and four internal proteins of influenza B virus: multiple cocirculating lineages and frequent reassortment of the NP, M, and NS genes. J Virol 73(3): 4413–4426.
13. Webster RG, Bean WJ, Gorman OT, Chambers TM, Kawaoka Y (1992) Evolution and Ecology of Influenza Viruses. Microbiol Rev 56(3): 152–179.
14. Connor RJ, Kawaoka Y, Webster RG, Paulson JC (1994) Receptor specificity in human, avian, and equine H2 and H3 influenza virus isolates. Virology 205: 17–29.
15. Hännönen C, Megas F, Ferry J (2004) Immunogenicity and protective efficacy of influenza vaccination. Virus Res 105(1–2): 133–138.
16. Fiore AE, Shay DK, Broder K, Iskander JK, Uyeki TM., et al. (2008) Prevention and control of influenza: recommendations of the Advisory Committee on Immunization Practices (ACIP). MMWR Recomm Rep 57: 1–60.
17. Wood JM, Schild GC, Neuman RW, Seagroatt V (1977) An improved single radial immunodiffusion technique for the assay of influenza haemagglutinin antigen: application for potency determinations of inactivated whole virus and subunit vaccines. J Biol Stand 5(3): 237–247.
18. Hardy S, Eichelberger M, Griffiths E, Weir JP, Wood D, et al. (2011) Confronting the next pandemic – Workshop on lessons learned from potency testing of pandemic (H1N1) 2009 influenza vaccines and considerations for future potency tests, Ottawa, Canada. July 27–29, 2010. Influenza Other Respi Viruses 5(6): 438–442 doi:10.1111/j.1750-2659.2011.00250.x.
19. Williams MS (1993) Single radial immunodiffusion as an in vitro potency assay for human inactivated influenza vaccines. Vet Microbiol 37(3–4): 233–262.
20. Wood JM, Duncan LA, Neuman RW, Riley AM, Robertson JS, et al. (1999) The influence of the host cell type on standardisation of influenza vaccine potency. Dev Biol Stand 98: 183–181.
21. La Montagne JR, Noble GR, Quinnin GV, Curlin GT, Blackwelder WC, et al. (1983) Summary of clinical trials of inactivated influenza vaccine – 1957. Rev Infect Dis 5(4): 723–736.
22. Cate TR, Couch RB, Parker D, Baxter B (1983) Reactogenicity, immunogenicity, and antibody persistence in adults given inactivated influenza virus vaccine – 1977. Rev Infect Dis 5(4): 737–750.
23. Wright PF, Cherry JD, Foy HM, Glezen WP, Hall CB, et al. (1983) Antigenicity and reactogenicity of influenza A/US77/97 virus in children – a multicentered evaluation of dosage and safety. Rev Infect Dis 5(4): 737–746.
24. Legastelois I, Chevalier M, Bernard MC, de Montfort A, Fouque M, et al. (2011) Glycoproteins and their Biological Relevance. Current Bioinformatics 6(4): 415–426.
25. Gravel C, Wang J, Li C, Wang J, Li X (2011) Antigenic stability of H1N1 pandemic virus correlates with vaccine strain. Vaccine 29(8): 1529–1533 doi:10.1016/j.vaccine.2010.12.120.
47. Quan FS, LiZN, Kim MC, Yang D, Compans RW, et al. (2011) Immunogenicity of low-pH treated whole viral influenza vaccine. Virology 417(1): 196–202 doi: 10.1016/j.virol.2011.05.014.

48. Blu A, Lemieux M, Li C, Li X, Wang J, et al. (2012) Modifying the thermostability of inactivated influenza vaccines. Vaccine 30: 5506–5511 doi: 10.1016/j.vaccine.2012.06.051.

49. Pukin AV, Weijers CA, van Lagen B, Wechselberger R, Sun B, et al. (2008) GM3, GM2 and GM1 mimics designed for biosensing: chemoenzymatic synthesis, target affinities and 900 MHz NMR analysis. Carbohydr Res 343(4): 636–650 doi: 10.1016/j.carres.2008.01.007.

50. Kakuta Y, Okino N, Kajiwara H, Ichikawa M, Takakura Y, et al. (2008) Crystal structure of Vibrionaceae Photobacterium sp. JT-ISH-224 alpha2,6-sialyltransferase in a ternary complex with donor product CMP and acceptor substrate lactose: catalytic mechanism and substrate recognition. Glycobiology 18(1): 66–73 doi: 10.1093/glycob/cwm119.

51. Tsukamoto H, Takakura Y, Mine T, Yamamoto T (2008) Photobacterium sp. JT-ISH-224 produces two sialyltransferases, alpha2,3-sialyltransferase and beta-galactoside alpha2,6-sialyltransferase. J Biochem 143(2): 187–197 doi: 10.1093/jb/mvm208.

52. Chan J, Lewis AR, Gilbert M, Karwaski MF, Bennet AJ (2010) A direct NMR method for the measurement of competitive kinetic isotope effects. Nat Chem Biol 6(6): 405–407 doi:10.1038/nchembio.352.

53. Zou W, Borrelli S, Gilbert M, Liu T, Pon RA, et al. (2004) Bioengineering of surface GD3 ganglioside for immunotargeting human melanoma cells. J Biol Chem 279(24): 25390–25399 doi: 10.1074/jbc.M402787200.

54. Zou W, Jennings HJ (1996) Mimics of the structural elements of Type III Group B Streptococcus capsular polysaccharide. Part II: Synthesis of a carboxylate-containing hexaaccharide with a short spacer. J Carbohydr Chem 15: 279–295 doi:10.1080/07328309608005653.

55. Hashem AM, Jaentschke B, Gravel C, Tocchi M, Doyle TM, et al. (2012) Subcutaneous immunization with recombinant adenovirus expressing influenza A nucleoprotein protects mice against lethal viral challenge. Hum Vaccin Immunother 8(4): 425–430.

56. Wood JM, Mummford J, Schild GC, Webster RG, Nicholson KG (1986) Single-radial-immunodiffusion potency tests of inactivated influenza vaccines for use in man and animals. Dev Biol Stand 64: 169–177.

57. Vivekanand PK, Diedrich P, Hindsdaul O (1996) Use of diethyl squarate for the coupling of oligosaccharide amines to carrier proteins and characterization of the resulting neoglycoproteins by MALDI-TOF mass spectrometry. Glycoconj J 13(2): 315–319.

58. Wang YF, Chang CF, Chi CY, Wang HC, Wang JR, et al. (2012) Characterization of glycan binding specificities of influenza B viruses with correlation with hemagglutinin genotypes and clinical features. J Med Virol 84(4): 679–685 doi: 10.1002/jmv.23219.

59. White JM, Wilson IA (1987) Anti-peptide antibodies detect steps in a protein conformational change: low-pH activation of the influenza virus hemagglutinin. J Cell Biol 105(6 Pt 2): 2897–2896.

60. Chen J, Lee KH, Steinhauser DA, Stevens DJ, Skehel JJ, et al. (1998) Structure of the hemagglutinin precursor cleavage site, a determinant of influenza pathogenicity and the origin of the labile conformation. Cell 95: 409–417 doi:10.1016/S0092-8674(00)81771-7.

61. Matrosovich MN, Gambaryan AS, Tuzikov AB, Byramova NE, Mochalova LV, et al. (1993) Probing of the receptor-binding sites of the H1 and H3 influenza A and influenza B virus hemagglutinins by synthetic and natural sialosides. Virology 195: 111–121.